Breaking News, Collaborations & Alliances

Affymax Earns Takeda Milestone

EMA accepts peginesatide MAA

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Affymax will receive a $5 million development milestone payment from Takeda Pharmaceutical under the companies’ global development and commercialization agreement for peginesatide. The milestone is triggered by the EMA acceptance of the MAA for the investigational compound peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.   “We are delighted with Takeda’s execution on the European front and are encouraged by the EMA acceptance of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters